Dosing & Uses
Dosage Forms & Strengths
Bleeding Esophageal Varices
20 mL maximum per session
Injections may be made at time of bleeding, then after 1 week, 6 week, 3 month and 6 month
Hepatic impairment (Child-Pugh Class C)/Concomitant cardiopulmonary disease: Reduce dose
Esophageal Varices (Orphan)
Orphan designation for prophylactic use in pediatric patients (aged 0 through 16 yr) with esophageal varices that are at risk of bleeding to obliterate varices and to prevent bleeding
- QOL Medical, LLC; 4445 North Highway A1A, 241; Vero Beach, FL 32963
Esophageal ulcer (2.1%)
Pleural effusion (2.1%)
Retrosternal pain (1.6%)
Esophageal stricture (1.3%)
Frequency not defined
Sloughing of the mucosa overlying the injected varix
Acute renal failure (reversible)
Hypersensitivity to ethanolamine oleate, oleic acid or ethanolamine
Not indicated for esophageal varices that have not bled
Risk of severe esophageal necrosis (potentially fatal)
Risk of severe aspiration pneumonia (potentially fatal especially in elderly)
Caution in hepatic impairment, cardiopulmonary disease, the elderly and critically ill patients
Submucosal injections not recommended
Extreme anaphylactic reaction may be treated with 0.25 mL of 1:1000 epinephrine IV & side effects controlled by antihistamines; fatal anaphylactic shock reported
Do not use if solution has particulate matter or discoloration
Pregnancy & Lactation
Pregnancy Category: C
Lactation: excretion in milk unknown; use with caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Sclerosing agent, produces a sterile inflammatory response leading to fibrosis and vein occlusion
Oleic acid is the inflammatory component
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.